Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of brivaracetam in epilepsy
NCT00150800Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2006
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy, sponsored by UCB. Primary endpoints: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) up to 11 years, Percentage of Participants Who Withdrew Due to an Adverse Event (AE) up to 11 years and 1 more. Started Jan 2006; status: completed.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT00150800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150800.